Hexis | $2,009,680 | (May 14, 2024)
Attovia Therapeutics | $105,000,000 | (May 14, 2024)
Active Surfaces | $5,600,000 | (May 14, 2024)
Kayentis
France
- Meylan, Auvergne-Rhone-Alpes
- 29/03/2023
- Unknown
- $5,416,000
Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) and Decentralized Clinical Trial solutions (DCTs), helps pharma, biotech and CROs bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2003, Kayentis has been active in clinical development, with a strong specialization in eCOA solutions for phases II/III across a broad range of therapeutic areas. Over the years, it has developed a full range of services and has enlarged its portfolio beyond eCOA solutions to support the new normal of decentralized and hybrid trials. The company has conducted digital data collection for over 280 clinical trials in 85 countries (18,000 sites and 98,000 patients), employing 120 languages. It has offices in the US (Boston), France (Grenoble) and Japan (Tokyo), and currently employs 185 staff.
- Industry Pharmaceutical Manufacturing
- Website https://kayentis.com/
- LinkedIn https://www.linkedin.com/company/kayentis/people/
Related People
Guillaume JugeFounder
France -
Grenoble, Auvergne-Rhône-Alpes
More than 25 years of experience of general management in large and small businesses in Healthcare and Life Sciences.
Expertise in starting and growing business, M&A, fund raising, building strong company culture
I strongly believe in CSR as a driver of companies' growth ; the combination of business, social and environmental care is the greatest way towards a balanced and lasting success.
Switchboard Health | $6,500,000 | (May 14, 2024)
ByHeart | $95,000,000 | (May 14, 2024)
Glacis Labs | $2,000,000 | (May 14, 2024)
Li Industries | $36,000,000 | (May 10, 2024)
Little Sparrows Technologies | $3,000,000 | (May 10, 2024)
Altera | $9,000,000 | (May 10, 2024)
Aardvark Therapeutics | $85,000,000 | (May 10, 2024)